| Cancer, Hypoxia, and Metabolism | Lifetime | 75 | JP 2 | 99.68 |
| Erythropoietin and Anemia Treatment | Lifetime | 11 | JP 1 | 99.53 |
| Renal Diseases and Glomerulopathies | Lifetime | 49 | JP 1 | 99.55 |
| Acute Kidney Injury Research | Lifetime | 28 | JP 1 | 99.45 |
| Chronic Kidney Disease and Diabetes | Lifetime | 55 | JP 1 | 99.56 |
| Dialysis and Renal Disease Management | Lifetime | 91 | JP 2 | 99.45 |
| Complement system in diseases | Lifetime | 59 | JP 4 | 98.98 |
| Advanced Glycation End Products research | Lifetime | 66 | JP 11 | 98.71 |
| Heme Oxygenase-1 and Carbon Monoxide | Lifetime | 81 | JP 8 | 98.43 |
| High Altitude and Hypoxia | Lifetime | 67 | JP 1 | 98.60 |
| Hemoglobinopathies and Related Disorders | Lifetime | 306 | JP 3 | 98.07 |
| Diabetes Treatment and Management | Lifetime | 335 | JP 12 | 98.71 |
| Biomedical Research and Pathophysiology | Lifetime | 98 | JP 4 | 97.20 |
| Blood transfusion and management | Lifetime | 193 | JP 1 | 96.93 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 490 | JP 25 | 97.08 |
| Renal and Vascular Pathologies | Lifetime | 549 | JP 7 | 96.88 |
| Iron Metabolism and Disorders | Lifetime | 636 | JP 7 | 96.52 |
| COVID-19 and healthcare impacts | Lifetime | 990 | JP 16 | 91.83 |
| Renin-Angiotensin System Studies | Lifetime | 451 | JP 55 | 96.00 |
| Potassium and Related Disorders | Lifetime | 352 | JP 8 | 93.57 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 617 | JP 58 | 90.40 |
| Neurological and metabolic disorders | Lifetime | 706 | JP 53 | 89.55 |
| Heterotopic Ossification and Related Conditions | Lifetime | 818 | JP 107 | 65.06 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 977 | JP 72 | 63.06 |
| Dialysis and Renal Disease Management | 2021-2025 | 13 | JP 1 | 99.61 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 5 | JP 1 | 99.34 |
| Blood transfusion and management | 2021-2025 | 7 | JP 1 | 98.65 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 25 | JP 1 | 99.33 |
| Diabetes Treatment and Management | 2021-2025 | 69 | JP 1 | 99.24 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 94 | JP 1 | 97.03 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 75 | JP 1 | 97.31 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 122 | JP 6 | 97.24 |
| Hormonal Regulation and Hypertension | 2021-2025 | 82 | JP 4 | 96.33 |
| Pancreatic function and diabetes | 2021-2025 | 171 | JP 1 | 96.61 |
| Iron Metabolism and Disorders | 2021-2025 | 98 | JP 2 | 95.57 |
| COVID-19 and healthcare impacts | 2021-2025 | 571 | JP 16 | 92.29 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 897 | JP 6 | 93.39 |
| Renal and Vascular Pathologies | 2021-2025 | 219 | JP 6 | 90.44 |
| Renal and related cancers | 2021-2025 | 406 | JP 21 | 89.35 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 466 | JP 26 | 87.79 |
| Advanced Glycation End Products research | 2021-2025 | 144 | JP 7 | 85.86 |
| Organ Donation and Transplantation | 2021-2025 | 416 | JP 8 | 87.18 |
| Mobile Health and mHealth Applications | 2021-2025 | 820 | JP 5 | 84.55 |
| Potassium and Related Disorders | 2021-2025 | 178 | JP 13 | 85.32 |
| Parathyroid Disorders and Treatments | 2021-2025 | 602 | JP 52 | 84.89 |
| Acute Kidney Injury Research | 2021-2025 | 748 | JP 11 | 78.62 |
| Pharmacology and Obesity Treatment | 2021-2025 | 341 | JP 6 | 77.86 |
| Central Venous Catheters and Hemodialysis | 2021-2025 | 852 | JP 32 | 76.59 |
| Biomedical Research and Pathophysiology | 2021-2025 | 156 | JP 4 | 74.74 |
| Biomedical Ethics and Regulation | 2021-2025 | 378 | JP 15 | 73.34 |
| Healthcare cost, quality, practices | 2021-2025 | 997 | JP 15 | 68.47 |
| Magnesium in Health and Disease | 2021-2025 | 204 | JP 19 | 67.78 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 366 | JP 27 | 65.59 |
| Ion Transport and Channel Regulation | 2021-2025 | 506 | JP 31 | 62.34 |
| Electrolyte and hormonal disorders | 2021-2025 | 896 | JP 54 | 60.75 |
| Heterotopic Ossification and Related Conditions | 2021-2025 | 169 | JP 16 | 57.72 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 774 | JP 34 | 58.09 |
| Nitric Oxide and Endothelin Effects | 2021-2025 | 815 | JP 20 | 54.96 |
| Alkaline Phosphatase Research Studies | 2021-2025 | 149 | JP 17 | 51.76 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 808 | JP 63 | 32.40 |